Maria Micaela Vina Romero
Overview
Explore the profile of Maria Micaela Vina Romero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Del Rosario Garcia B, Vina Romero M, Gonzalez Rosa V, Alarcon Payer C, Oliva Oliva L, Nazco Casariego G, et al.
Farm Hosp
. 2025 Jan;
PMID: 39880783
Aims: Tyrosine kinase inhibitors (TKIs) have been successful in changing the course of chronic myeloid leukaemia (CML) due to their high efficacy. However, their effectiveness is conditioned by adherence to...
2.
Del Rosario Garcia B, Vina Romero M, Gonzalez Rosa V, Alarcon Payer C, Oliva Oliva L, Merino Alonso F, et al.
J Oncol Pharm Pract
. 2023 Sep;
30(5):902-906.
PMID: 37748859
Objective: Tyrosine kinase inhibitors (TKIs) have successfully changed the natural course of chronic myeloid leukaemia (CML). Although they are highly effective drugs, their clinical benefit is conditioned by adherence. This...
3.
Del Rosario Garcia B, Morales Barrios J, Cruz Jurado J, Diaz R, Vina Romero M, Padron I, et al.
J Oncol Pharm Pract
. 2022 Dec;
29(7):1613-1618.
PMID: 36482704
Objectives: Imatinib is the first therapeutic option for the treatment of unresectable or metastatic gastrointestinal stromal tumours. Previous studies have shown an improvement in patient survival rates following the use...
4.
Del Rosario Garcia B, Gonzalez Garcia I, Vina Romero M, Gonzalez Garcia J, Diaz R, Padron I, et al.
J Oncol Pharm Pract
. 2021 Oct;
29(1):40-44.
PMID: 34661491
Introduction: The addition of imatinib to the therapeutic arsenal for chronic myeloid leukaemia (CML) has changed the natural course of the disease, in such a way that it is now...
5.
Ferrer Machin A, Vina Romero M, Liminana E, Alonso J
Nefrologia (Engl Ed)
. 2020 Jun;
41(1):79-80.
PMID: 32513510
No abstract available.
6.
Gonzalez Garcia J, Gutierrez Nicolas F, Diaz R, Nazco Casariego G, Vina Romero M, Llabres Martinez M, et al.
Ann Pharmacother
. 2020 Jan;
54(8):775-779.
PMID: 31971005
Subcutaneous trastuzumab (T-SC) administration does not allow the historical target concentration of 20 µg/mL for efficacy to be reached, from the start of treatment in patients with a body mass...
7.
Gutierrez Nicolas F, Nazco Casariego G, Vina Romero M, Gonzalez Garcia J, Diaz R, Perez Perez J
Eur J Hosp Pharm
. 2019 Jun;
23(3):131-133.
PMID: 31156833
Introduction: The advent of Luer-type needleless venous access catheters has been accompanied by a growing number of catheter-related bloodstream infections. Our main objective was to compare rates of colonisation and...
8.
Vina Romero M, Garcia Gil S, Nazco Casariego G, Alonso J, Gutierrez Nicolas F
An Pediatr (Engl Ed)
. 2018 Apr;
90(3):187-188.
PMID: 29705180
No abstract available.
9.
Garcia Gil S, Diaz R, Nazco Casariego G, Llanos Munoz M, Vina Romero M, Martin Calero B, et al.
Med Clin (Barc)
. 2018 Mar;
151(11):425-430.
PMID: 29499902
Background And Objectives: Evaluate the relationship between the presence of polymorphisms in genes involved in the pharmacodynamics of irinotecan (UGT1A, SLCO1B1, ABCB1 and ABCC2) and the safety of irinotecan in...